Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 303, Issue 6, 2012, Pages

  Abid, Shariq ^a   Houssaini, Amal ^a   Chevarin, Caroline ^b   Marcos, Elisabeth ^a   Tissot, Claire Marie ^a   Gary Bobo, Guillaume ^a   Wan, Feng ^a   Mouraret, Nathalie ^a   Amsellem, Valerie ^a   Dubois Randé, Jean Luc ^a   Hamon, Michel ^b   Adnot, Serge ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Pulmonary vascular remodeling; Serotonin synthesis; Serotonin transporter; Transgenic mice; Tryptophan hydroxylase

Indexed keywords

2 AMINO 3 [4 [2 AMINO 6 [2,2,2 TRIFLUORO 1 (3' FLUOROBIPHENYL 4 YL)ETHOXY]PYRIMIDIN 4 YL]PHENYL]PROPANOIC ACID; CITALOPRAM; ENZYME INHIBITOR; LP 533401; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEROTONIN BLOOD LEVEL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; ANOXIA; CITALOPRAM; DUODENUM; HYPERTENSION, PULMONARY; LUNG; MICE; MICE, INBRED C57BL; PYRIMIDINES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN HYDROXYLASE;

EID: 84866395115     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00049.2012     Document Type: Article

References (30)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609-616, 1996.
2. Alvarez JC, Sanceaume M, Advenier C, Spreux-Varoquaux O. Differential changes in brain and platelet 5-HT concentrations after steadystate achievement and repeated administration of antidepressant drugs in mice. Eur Neuropsychopharmacol 10: 31-36, 1999.
3. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche M, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G. Disruption of the nonneuronal Tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA 100: 13525-13530, 2003.
4. Darmon MC, Guibert B, Leviel V, Ehret M, Maitre M, Mallet J. Sequence of two mRNAs encoding active rat tryptophan hydroxylase. J Neurochem 51: 312-316, 1988.
5. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res 84: 329-336, 1999.
6. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113: 1857-1864, 2006.
7. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105: 1555-1562, 2000.
8. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150, 2001.
9. Fanburg B, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol Lung Cell Mol Physiol 272: L795-L806, 1997.
10. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351: 1655-1665, 2004.
11. Gary-Bobo G, Houssaini A, Amsellem V, Rideau D, Pacaud P, Perrin A, Bregeon J, Marcos E, Dubois-Rande JL, Sitbon O, Savale L, Adnot S. Effects of HIV protease inhibitors on progression of monocrotaline-and hypoxia-induced pulmonary hypertension in rats. Circulation 122: 1937-1947, 2010.
12. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13, Suppl 2: 15-30, 1999.
13. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330, 2006.
14. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819, 2005.
15. Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α-targeted overexpression of the serotonin transporter. FASEB J 23: 4135-4147, 2009.
16. Hamon M, Fattaccini C, Adrien J, Gallissot M, Martin P, Gozlan H. Alterations in central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther 246: 745-752, 1988.
17. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254, 1995.
18. Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur AM, Saurini F, Eddahibi S, Hamon M, Adnot S. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293: L1045-L1052, 2007.
19. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8: 1129-1135, 2002.
20. Lee SL, Wang W, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277: L282-L291, 1999.
21. Lee SL, Wang WW, Fanburg BL. Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 24: 855-858, 1998.
22. Lee SL, Wang WW, Moore BJ, Fanburg BL. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res 68: 1362-1368, 1991.
23. Liu Q, Yang Q, Zambrowicz B, Shi Z. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325: 47-55, 2008.
24. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119: 917-930, 1996.
25. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168: 487-493, 2003.
26. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49: 232-236, 2007.
27. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-S31, 2009.
28. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 145: 793-797, 1992.
29. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299: 76, 2003.
30. Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16: 308-312, 2010.